FI114610B - Menetelmä beta-fenyylipropiofenonijohdannaisia sisältävien retardmikrotablettien valmistamiseksi - Google Patents
Menetelmä beta-fenyylipropiofenonijohdannaisia sisältävien retardmikrotablettien valmistamiseksi Download PDFInfo
- Publication number
- FI114610B FI114610B FI954686A FI954686A FI114610B FI 114610 B FI114610 B FI 114610B FI 954686 A FI954686 A FI 954686A FI 954686 A FI954686 A FI 954686A FI 114610 B FI114610 B FI 114610B
- Authority
- FI
- Finland
- Prior art keywords
- weight
- release
- active substance
- active ingredient
- tablet
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 21
- QGGZBXOADPVUPN-UHFFFAOYSA-N dihydrochalcone Chemical class C=1C=CC=CC=1C(=O)CCC1=CC=CC=C1 QGGZBXOADPVUPN-UHFFFAOYSA-N 0.000 title claims abstract description 5
- 238000002360 preparation method Methods 0.000 title claims description 16
- 230000008569 process Effects 0.000 title claims description 12
- 239000007903 gelatin capsule Substances 0.000 claims abstract description 7
- 239000011248 coating agent Substances 0.000 claims abstract description 5
- 238000000576 coating method Methods 0.000 claims abstract description 5
- 150000003839 salts Chemical class 0.000 claims abstract description 3
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims abstract 2
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims abstract 2
- 239000013543 active substance Substances 0.000 claims description 9
- 239000008187 granular material Substances 0.000 claims description 9
- 230000000979 retarding effect Effects 0.000 claims description 6
- 230000036470 plasma concentration Effects 0.000 claims description 5
- 235000013305 food Nutrition 0.000 claims description 4
- XWIHRGFIPXWGEF-UHFFFAOYSA-N propafenone hydrochloride Chemical group Cl.CCCNCC(O)COC1=CC=CC=C1C(=O)CCC1=CC=CC=C1 XWIHRGFIPXWGEF-UHFFFAOYSA-N 0.000 claims description 4
- 229960002443 propafenone hydrochloride Drugs 0.000 claims description 4
- 230000008901 benefit Effects 0.000 claims description 3
- 238000001727 in vivo Methods 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 2
- 239000008240 homogeneous mixture Substances 0.000 claims 1
- 239000002002 slurry Substances 0.000 claims 1
- 239000006188 syrup Substances 0.000 claims 1
- 235000020357 syrup Nutrition 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 abstract description 28
- 239000003826 tablet Substances 0.000 abstract description 26
- 238000004519 manufacturing process Methods 0.000 abstract description 7
- 239000000654 additive Substances 0.000 abstract description 4
- 239000000314 lubricant Substances 0.000 abstract description 3
- 239000007950 delayed release tablet Substances 0.000 abstract 1
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 30
- 229960000203 propafenone Drugs 0.000 description 21
- JWHAUXFOSRPERK-UHFFFAOYSA-N propafenone Chemical compound CCCNCC(O)COC1=CC=CC=C1C(=O)CCC1=CC=CC=C1 JWHAUXFOSRPERK-UHFFFAOYSA-N 0.000 description 21
- 239000000203 mixture Substances 0.000 description 17
- 235000019359 magnesium stearate Nutrition 0.000 description 15
- 239000003795 chemical substances by application Substances 0.000 description 11
- 230000002035 prolonged effect Effects 0.000 description 8
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 7
- -1 polyethylene Polymers 0.000 description 7
- 238000007906 compression Methods 0.000 description 6
- 230000006835 compression Effects 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 239000011159 matrix material Substances 0.000 description 6
- 238000011049 filling Methods 0.000 description 5
- 229920000159 gelatin Polymers 0.000 description 5
- 235000019322 gelatine Nutrition 0.000 description 5
- 238000005469 granulation Methods 0.000 description 5
- 230000003179 granulation Effects 0.000 description 5
- 108010010803 Gelatin Proteins 0.000 description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 4
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 4
- 239000008108 microcrystalline cellulose Substances 0.000 description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000007941 film coated tablet Substances 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 229920001993 poloxamer 188 Polymers 0.000 description 3
- 229940044519 poloxamer 188 Drugs 0.000 description 3
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
- 229920003152 Eudragit® RS polymer Polymers 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 238000005054 agglomeration Methods 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 235000019700 dicalcium phosphate Nutrition 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 239000004922 lacquer Substances 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 229940005550 sodium alginate Drugs 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000008051 alkyl sulfates Chemical class 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium group Chemical group [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- HLKZFSVWBQSKKH-UHFFFAOYSA-N but-3-enoic acid;1-ethenylpyrrolidin-2-one Chemical compound OC(=O)CC=C.C=CN1CCCC1=O HLKZFSVWBQSKKH-UHFFFAOYSA-N 0.000 description 1
- 229940061587 calcium behenate Drugs 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- SMBKCSPGKDEPFO-UHFFFAOYSA-L calcium;docosanoate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCCCCCC([O-])=O SMBKCSPGKDEPFO-UHFFFAOYSA-L 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229960002908 cimetidine hydrochloride Drugs 0.000 description 1
- QJHCNBWLPSXHBL-UHFFFAOYSA-N cimetidine hydrochloride Chemical compound [H+].[Cl-].N#C/N=C(/NC)NCCSCC=1N=CNC=1C QJHCNBWLPSXHBL-UHFFFAOYSA-N 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- FSXVSUSRJXIJHB-UHFFFAOYSA-M ethyl prop-2-enoate;methyl 2-methylprop-2-enoate;trimethyl-[2-(2-methylprop-2-enoyloxy)ethyl]azanium;chloride Chemical compound [Cl-].CCOC(=O)C=C.COC(=O)C(C)=C.CC(=C)C(=O)OCC[N+](C)(C)C FSXVSUSRJXIJHB-UHFFFAOYSA-M 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000007948 fast release tablet Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 229940127021 low-dose drug Drugs 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 125000005397 methacrylic acid ester group Chemical group 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- YTSACTNRGUJEGO-UHFFFAOYSA-N oxirane prop-1-ene Chemical group CC=C.C1CO1 YTSACTNRGUJEGO-UHFFFAOYSA-N 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- OKODKVMXHLUQSW-JITBQSAISA-M sodium;(e)-4-hydroxy-4-oxobut-2-enoate;octadecanoic acid Chemical compound [Na+].OC(=O)\C=C\C([O-])=O.CCCCCCCCCCCCCCCCCC(O)=O OKODKVMXHLUQSW-JITBQSAISA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000007939 sustained release tablet Substances 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002966 varnish Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Saccharide Compounds (AREA)
- Silicates, Zeolites, And Molecular Sieves (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Manufacturing Of Micro-Capsules (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE4310963 | 1993-04-03 | ||
| DE4310963A DE4310963C2 (de) | 1993-04-03 | 1993-04-03 | Retardmikrotablette von beta-Phenylpropiophenonderivaten |
| PCT/EP1994/000949 WO1994022434A1 (de) | 1993-04-03 | 1994-03-24 | RETARDMIKROTABLETTE VON β-PHENYLPROPIOPHENONDERIVATEN |
| EP9400949 | 1994-03-24 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI954686L FI954686L (fi) | 1995-10-02 |
| FI954686A0 FI954686A0 (fi) | 1995-10-02 |
| FI114610B true FI114610B (fi) | 2004-11-30 |
Family
ID=6484646
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI954686A FI114610B (fi) | 1993-04-03 | 1995-10-02 | Menetelmä beta-fenyylipropiofenonijohdannaisia sisältävien retardmikrotablettien valmistamiseksi |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US5681588A (cs) |
| EP (1) | EP0691843B1 (cs) |
| JP (1) | JP3625825B2 (cs) |
| KR (1) | KR100315618B1 (cs) |
| CN (1) | CN1092957C (cs) |
| AT (1) | ATE148988T1 (cs) |
| AU (1) | AU678227B2 (cs) |
| BR (2) | BR9406036A (cs) |
| CA (1) | CA2158166C (cs) |
| CZ (1) | CZ284869B6 (cs) |
| DE (2) | DE4310963C2 (cs) |
| DK (1) | DK0691843T3 (cs) |
| ES (1) | ES2098930T3 (cs) |
| FI (1) | FI114610B (cs) |
| GR (1) | GR3023339T3 (cs) |
| HR (1) | HRP940198B1 (cs) |
| HU (1) | HU221590B (cs) |
| IL (2) | IL109097A0 (cs) |
| NO (1) | NO306848B1 (cs) |
| NZ (1) | NZ263565A (cs) |
| PL (1) | PL175219B1 (cs) |
| RU (1) | RU2157191C2 (cs) |
| SG (1) | SG43955A1 (cs) |
| SI (1) | SI9420027A (cs) |
| TW (1) | TW266159B (cs) |
| UA (1) | UA40616C2 (cs) |
| WO (1) | WO1994022434A1 (cs) |
| ZA (1) | ZA942293B (cs) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5837292A (en) * | 1996-07-03 | 1998-11-17 | Yamanouchi Europe B.V. | Granulate for the preparation of fast-disintegrating and fast-dissolving compositions containing a high amount of drug |
| JP4331930B2 (ja) * | 2001-10-17 | 2009-09-16 | 武田薬品工業株式会社 | 酸に不安定な薬物の高含量顆粒 |
| US20050226923A1 (en) * | 2004-04-07 | 2005-10-13 | Gassert Chad M | Venlafaxine compositions in the form of microtablets |
| CA2469339A1 (en) * | 2004-06-07 | 2005-12-07 | Bernard Charles Sherman | Sustained release propafenone hydrochloride capsules |
| CA2469327A1 (en) * | 2004-06-07 | 2005-12-07 | Bernard Charles Sherman | Propafenone hydrochloride capsules containing microtablets |
| DE102006006532B4 (de) | 2006-02-10 | 2007-11-08 | Biogenerics Pharma Gmbh | Pharmazeutische Zubereitung |
| WO2007103557A2 (en) | 2006-03-09 | 2007-09-13 | Reliant Pharmaceuticals, Inc. | Coating capsules with active pharmaceutical ingredients |
| US20080014257A1 (en) * | 2006-07-14 | 2008-01-17 | Par Pharmaceutical, Inc. | Oral dosage forms |
| US20090035370A1 (en) * | 2007-08-02 | 2009-02-05 | Drugtech Corporation | Dosage form and method of use |
| WO2010043950A2 (en) | 2008-10-15 | 2010-04-22 | Aizant Drug Research Solutions Private Limited | Propafenone extended release composition |
| CN103908443A (zh) * | 2013-11-25 | 2014-07-09 | 力品药业（厦门）有限公司 | 一种盐酸普罗帕酮缓释胶囊及其制备方法 |
| CN107441051B (zh) * | 2016-05-30 | 2022-09-16 | 北京科信必成医药科技发展有限公司 | 一种盐酸普罗帕酮微片及其制备方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3951821A (en) * | 1972-07-14 | 1976-04-20 | The Dow Chemical Company | Disintegrating agent for tablets |
| DE3210061A1 (de) * | 1982-03-19 | 1983-09-22 | Basf Ag, 6700 Ludwigshafen | Verfahren zur herstellung von propafenon |
| DE3422619A1 (de) * | 1984-06-19 | 1985-12-19 | Basf Ag, 6700 Ludwigshafen | Zylindrische mikrotabletten |
| GB2176999B (en) * | 1985-06-22 | 1989-07-12 | Stanley Stewart Davis | Sustained release medicament |
| US4753801A (en) * | 1985-10-25 | 1988-06-28 | Eli Lilly And Company | Sustained release tablets |
| DE3725273A1 (de) * | 1987-07-30 | 1989-02-09 | Basf Ag | Verfahren zur synthese von enantiomeren des propafenons sowie diese enthaltende therapeutische mittel |
| DE3809764A1 (de) * | 1988-03-23 | 1989-10-05 | Knoll Ag | Mischung aus alginaten und polyacrylaten und deren verwendung |
| US4954347A (en) * | 1988-05-03 | 1990-09-04 | Basf K & F Corp. | Long lasting composition of propafenone and quinidine for treatment of cardiac conditions |
| DE3911069A1 (de) * | 1989-04-06 | 1990-10-11 | Knoll Ag | Einkristalle von ss-phenylpropiophenonen |
| DE59005781D1 (de) * | 1990-07-02 | 1994-06-23 | Boehringer Mannheim Gmbh | Verfahren zur herstellung geformter, verpresster dosiseinheiten mit retardierter freisetzung und entsprechende dosiseinheit. |
| DE4021678C2 (de) * | 1990-07-07 | 1994-07-07 | Merz & Co Gmbh & Co | Verfahren zur Herstellung klein dimensionierter Formkörper mit hohem Etofibrat-Gehalt und kontrollierter Wirkstoff-Freisetzung, deren Verwendung und daraus bestehende oral verabreichbare Applikationsformen |
| IT1250483B (it) * | 1990-08-30 | 1995-04-07 | Eurand Int | Sistema di ritardo a matrice multipla |
-
1993
- 1993-03-23 IL IL10909793A patent/IL109097A0/xx unknown
- 1993-04-03 DE DE4310963A patent/DE4310963C2/de not_active Expired - Lifetime
-
1994
- 1994-03-23 IL IL10909794A patent/IL109097A/en not_active IP Right Cessation
- 1994-03-23 TW TW083102550A patent/TW266159B/zh not_active IP Right Cessation
- 1994-03-24 AT AT94911955T patent/ATE148988T1/de active
- 1994-03-24 ES ES94911955T patent/ES2098930T3/es not_active Expired - Lifetime
- 1994-03-24 DE DE59401833T patent/DE59401833D1/de not_active Expired - Lifetime
- 1994-03-24 JP JP51843894A patent/JP3625825B2/ja not_active Expired - Lifetime
- 1994-03-24 WO PCT/EP1994/000949 patent/WO1994022434A1/de not_active Ceased
- 1994-03-24 UA UA95114786A patent/UA40616C2/uk unknown
- 1994-03-24 SG SG1996007053A patent/SG43955A1/en unknown
- 1994-03-24 CA CA002158166A patent/CA2158166C/en not_active Expired - Lifetime
- 1994-03-24 NZ NZ263565A patent/NZ263565A/en not_active IP Right Cessation
- 1994-03-24 US US08/525,749 patent/US5681588A/en not_active Expired - Lifetime
- 1994-03-24 SI SI9420027A patent/SI9420027A/sl unknown
- 1994-03-24 RU RU95122468/14A patent/RU2157191C2/ru active
- 1994-03-24 CZ CZ952465A patent/CZ284869B6/cs not_active IP Right Cessation
- 1994-03-24 CN CN94191661A patent/CN1092957C/zh not_active Expired - Lifetime
- 1994-03-24 EP EP94911955A patent/EP0691843B1/de not_active Expired - Lifetime
- 1994-03-24 KR KR1019950704271A patent/KR100315618B1/ko not_active Expired - Lifetime
- 1994-03-24 HU HU9502879A patent/HU221590B/hu unknown
- 1994-03-24 AU AU64295/94A patent/AU678227B2/en not_active Expired
- 1994-03-24 BR BR9406036A patent/BR9406036A/pt not_active Application Discontinuation
- 1994-03-24 DK DK94911955.6T patent/DK0691843T3/da active
- 1994-03-24 PL PL94310966A patent/PL175219B1/pl unknown
- 1994-03-25 HR HRP4310963.2A patent/HRP940198B1/xx not_active IP Right Cessation
- 1994-03-31 ZA ZA942293A patent/ZA942293B/xx unknown
-
1995
- 1995-10-02 NO NO953910A patent/NO306848B1/no not_active IP Right Cessation
- 1995-10-02 FI FI954686A patent/FI114610B/fi not_active IP Right Cessation
-
1997
- 1997-04-22 BR BR1100303-0A patent/BR1100303A/pt active IP Right Grant
- 1997-05-05 GR GR970400996T patent/GR3023339T3/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1121104B1 (en) | New controlled release oral formulations for rivastigmine | |
| US20010038852A1 (en) | Solid oral dosage forms with delayed release of active ingredient and high mechanical stability | |
| US20090124702A1 (en) | Pharmaceutical Compositions of Metformin | |
| RS51973B (sr) | Stabilni farmaceutski preparati koji sadrže fezoterodin | |
| US6713086B2 (en) | Controlled release formulation of divalproex sodium | |
| US6528090B2 (en) | Controlled release formulation of divalproex sodium | |
| FI114610B (fi) | Menetelmä beta-fenyylipropiofenonijohdannaisia sisältävien retardmikrotablettien valmistamiseksi | |
| US9387166B2 (en) | Controlled release oral dosage form comprising oxycodone | |
| SK3722001A3 (en) | Multiple unit controlled food effect-independent release pharmaceutical preparations and method for preparing the same | |
| AU2004315136B2 (en) | Extended release coated microtablets of venlafaxine hydrochloride | |
| BG107372A (bg) | Препарати със забавено действие на хинолонови антибиотици и метод за получаването им | |
| ES2992213T3 (es) | Composición que comprende ramipril e indapamida | |
| ES2321908T3 (es) | Preparaciones farmaceuticas de liberacion prolongada independientemente del ph. | |
| RU2352338C2 (ru) | Лекарственная композиция, содержащая флупиртин, с контролируемым высвобождением биологически активного вещества | |
| WO2005084636A2 (en) | A process for the preparation of controlled-release pharmaceutical composition of metoprolol | |
| Giunchedi et al. | Hydrophilic matrices for the extended release of a model drug exhibiting pH-dependent solubility | |
| RU2435584C2 (ru) | Пролонгированная фармацевтическая композиция, лекарственная форма и способ ее изготовления (варианты) | |
| JP2005528388A (ja) | 改善された制御放出調製物 | |
| CA2437412C (en) | Delayed release microtablet of b-phenylpropiophenone derivatives | |
| SK11072000A3 (sk) | Tiagabínové prostriedky s predĺženým uvoľňovaním so zníženými vedľajšími účinkami | |
| CA2635949A1 (en) | Controlled release formulation of divalproic acid and its derivatives | |
| HU230983B1 (hu) | Módosított hatóanyag-leadású gyógyszerkészítmény | |
| NZ718686B2 (en) | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof | |
| HK1091137B (en) | Extended release coated minitablets of venlafaxine hydrochloride |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Patent granted |
Ref document number: 114610 Country of ref document: FI |
|
| MA | Patent expired |